Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Mind Medicine Mindmed Inc (MMEDF)

Mind Medicine Mindmed Inc (MMEDF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2911 +20.23%
on 06/18/20
0.4000 -12.50%
on 07/02/20
-0.0138 (-3.79%)
since 06/05/20
3-Month
0.2911 +20.23%
on 06/18/20
1.0000 -65.00%
on 04/24/20
-0.0500 (-12.50%)
since 04/07/20

Most Recent Stories

More News
MindMed Building Diverse Pipeline and Leadership Position in Psychedelic Inspired Medicines Industry

MindMed Co-founders and Co-CEOs JR Rahn and Stephen Hurst to provide corporate update of activities and investor Q&A on July 2, 2020 at 1pm EDT

MMEDF : 0.3500 (-3.05%)
Psychedelic Medicine Stocks Garner Serious Investor Interest

, /PRNewswire/ -- Investor interest in alternative psychedelic medicine is on the rise, with billionaire investors, celebrities, and high-profile execs endorsing the psychedelic medicine market either...

PYPL : 178.03 (+1.05%)
PFE : 34.03 (-1.39%)
MYCO.CN : 0.830 (+6.41%)
NLBIF : 0.6150 (-6.82%)
NFLX : 493.30 (-0.10%)
MMEDF : 0.3500 (-3.05%)
Psychedelic Drugs Market Projected to Reach $6.85 Billion by 2027

, /PRNewswire/ -- The psychedelic drugs market is projected to grow at a CAGR of 16.3% over the next eight years to , according to Data Bridge Market Research. The key factors that will fuel this growth...

AGN : 193.02 (+0.02%)
JNJ : 143.00 (+0.01%)
NUMI.VN : 0.350 (-6.67%)
LKYSD : 0.3330 (+17.54%)
PEMTF : 0.1620 (-4.71%)
MOTA.CN : 0.225 (-2.17%)
ABBV : 99.35 (+0.34%)
MMEDF : 0.3500 (-3.05%)
MindMed Developing IP For Personalized Psychedelic Assisted Therapies

MindMed, in collaboration with the University Hospital Basel, has filed two separate patent applications for technologies to screen and optimize the dosing of MDMA and LSD

MMEDF : 0.3500 (-3.05%)
BGHM : 0.4600 (+12.20%)
Rising Anxiety & Mental Health Issues are a Growing Concern as People Continue to Work From Home

, /PRNewswire/ -- As pandemic-related social distancing measures continue, employers across the globe are extending work from home orders. (NASDAQ:MSFT) is until October, while tech giants like Google...

ZOOM : 10.4000 (+23.81%)
LLY : 166.75 (-0.08%)
FB : 238.50 (-0.74%)
MSFT : 212.13 (+0.68%)
MMEDF : 0.3500 (-3.05%)
MindMed To Evaluate Ayahuasca's Active Ingredient DMT In Phase 1 Clinical Trial Collaboration

Phase 1 Trial to experiment with dosing methods to better understand how humans react to DMT, setting stage for future potential Phase 2a proof of concept trials

MMEDF : 0.3500 (-3.05%)
Recent Studies Indicating CBD may be Better Therapy for Treating Anxiety Than Medical Marijuana

, /PRNewswire/ -- Researchers have been looking at more and more uses for medical marijuana in recent years. Marijuana can affect the body in many ways beyond just getting the user high. The high feeling...

SHRMF : 0.5800 (-3.81%)
SHRM.CN : 0.890 (+3.49%)
RTSL : 0.9000 (-7.22%)
CGC : 16.50 (-2.60%)
WEED.TO : 22.42 (-2.31%)
OGI : 1.5900 (+1.92%)
OGI.TO : 2.17 (+3.33%)
MMEDF : 0.3500 (-3.05%)
Psychedelic-derived Therapies are Just What the Doctor Ordered to Address a Historic Mental Illness Epidemic

, /PRNewswire/ -- While the global death toll caused by the pandemic is well-publicized, a lesser-known side effect of the ongoing pandemic is the rise in mental illness that it has generated. Due to...

SEEL : 1.0200 (-2.86%)
SHRM.CN : 0.890 (+3.49%)
SHRMF : 0.5800 (-3.81%)
NUMI.VN : 0.350 (-6.67%)
LKYSD : 0.3330 (+17.54%)
JNJ : 143.00 (+0.01%)
MMEDF : 0.3500 (-3.05%)
Phase 2 Clinical Trial of LSD for "Suicide Headaches" Begins Treating Patients

MindMed Is Collaborating on a Phase 2 Clinical Trial of LSD For Cluster Headaches with University Hospital Basel's Liechti Lab

MMEDF : 0.3500 (-3.05%)
BGHM : 0.4600 (+12.20%)
Psychedelic Medicine and the Future of Mental Health Care Looks Promising

, /PRNewswire/ -- After decades of having a bad rep, psychedelics are making their way back into the medical world and are being touted for For years, Big Pharma companies (NYSE:PFE), (NYSE:TAK),(NYSE:TEVA)...

TKPYY : 16.5900 (-0.90%)
TAK : 17.49 (-0.96%)
ABBV : 99.35 (+0.34%)
TEVA : 11.21 (-2.69%)
PFE : 34.03 (-1.39%)
MMEDF : 0.3500 (-3.05%)
Trade MMEDF with:

Key Turning Points

2nd Resistance Point 0.4003
1st Resistance Point 0.3807
Last Price 0.3500
1st Support Level 0.3507
2nd Support Level 0.3403

See More

52-Week High 1.0000
Fibonacci 61.8% 0.6498
Fibonacci 50% 0.5416
Fibonacci 38.2% 0.4335
Last Price 0.3500
52-Week Low 0.0833

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar